Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF

There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Mediterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases associated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yılmaz, Sedat, Tekgöz, Emre, Çınar, Muhammet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267750/
https://www.ncbi.nlm.nih.gov/pubmed/30071938
http://dx.doi.org/10.5152/eurjrheum.2018.17183
_version_ 1783376147073990656
author Yılmaz, Sedat
Tekgöz, Emre
Çınar, Muhammet
author_facet Yılmaz, Sedat
Tekgöz, Emre
Çınar, Muhammet
author_sort Yılmaz, Sedat
collection PubMed
description There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Mediterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases associated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to the normalization of amyloidosis-related symptoms, but proteinuria re-occurred eventually. Fortunately, the patients responded to tocilizumab re-treatment. This led us to conclude that physicians should not stop the treatment, even in patients with normalized proteinuria levels.
format Online
Article
Text
id pubmed-6267750
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medical Research and Education Association
record_format MEDLINE/PubMed
spelling pubmed-62677502018-12-06 Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF Yılmaz, Sedat Tekgöz, Emre Çınar, Muhammet Eur J Rheumatol Case Report There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Mediterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases associated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to the normalization of amyloidosis-related symptoms, but proteinuria re-occurred eventually. Fortunately, the patients responded to tocilizumab re-treatment. This led us to conclude that physicians should not stop the treatment, even in patients with normalized proteinuria levels. Medical Research and Education Association 2018-12 2018-07-20 /pmc/articles/PMC6267750/ /pubmed/30071938 http://dx.doi.org/10.5152/eurjrheum.2018.17183 Text en © Copyright by 2018 Medical Research and Education Association http://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Case Report
Yılmaz, Sedat
Tekgöz, Emre
Çınar, Muhammet
Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
title Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
title_full Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
title_fullStr Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
title_full_unstemmed Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
title_short Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF
title_sort recurrence of proteinuria after cessation of tocilizumab in patients with aa amyloidosis secondary to fmf
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267750/
https://www.ncbi.nlm.nih.gov/pubmed/30071938
http://dx.doi.org/10.5152/eurjrheum.2018.17183
work_keys_str_mv AT yılmazsedat recurrenceofproteinuriaaftercessationoftocilizumabinpatientswithaaamyloidosissecondarytofmf
AT tekgozemre recurrenceofproteinuriaaftercessationoftocilizumabinpatientswithaaamyloidosissecondarytofmf
AT cınarmuhammet recurrenceofproteinuriaaftercessationoftocilizumabinpatientswithaaamyloidosissecondarytofmf

Ejemplares similares